The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

In the news

Podcast with Ian Crosbie – 21/01/2022
“Water, Water, Everywhere – Innovations in Treating Diuretic Resistant Fluid Overload” featuring Ian Crosbie

Listen podcast

Bolero Biotech event – October 2021
Bolero Biotech Event featuring Ian Crosbie, CEO Sequana Medical – timeslot 00:43:12 – 01:21:27

Watch video

De Belegger on Tour – 20/09/2021
Pitch Ian Crosbie during “De Belegger on tour”

Go to news

Edison TV – 28/07/2021
Sequana Medical – executive interview

Go to news

Kanaal Z – 04/02/2021
Sequana Medical opent deur naar behandeling hartaandoeningen

Go to news

Kanaal Z – 23/01/2020
Sequana haalt forst kapitaal op, aan forse korting ook

Go to news

Kanaal Z – 15 /10/2018
Zwitsers medtechbedrijf Sequana kiest voor Gent

Go to news



    We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

    The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.